MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cmi.2024.09.025

Медицинская библиотека · Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024

Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward.

Tängdén Thomas, Carrara Elena, Hellou Mona Mustafa, Yahav Dafna, Paul Mical

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Following intense efforts to revive the dry antibiotic research and development pipeline, a few highly awaited antibiotics with activity against multidrug-resistant (MDR) bacteria were recently approved.

OBJECTIVES

We aim to highlight gaps in the evidence generated for new antibiotics by the time of their approval and to review the consequent limitations of treatment guidelines for priority MDR bacteria. We also report on the availability of the new antibiotics, reimbursement strategies allowing the use of these antibiotics in hospitals, and antibiotic stewardship efforts.

SOURCES: We searched PubMed for phase 3 randomized controlled trials, guidelines, and publications on access, usage, regulatory aspects and antimicrobial stewardship of antibiotics approved for use against MDR bacteria between 2013 and 2023. Other sources included governmental and professional documents regarding policies for reimbursement and use of the new antibiotics.

CONTENT: Several gaps in the evidence available regarding the new antibiotics are described related to the trials' target populations, comparators, management algorithm within the trial, non-inferiority hypotheses, and assessment of resistance development within the studies. We highlight the risk of current guidelines to increase the usage of new antibiotics and consequently accelerate resistance development. Updated mapping of antibiotic availability reveals critical inequality in access to the new antibiotics. Finally, strategies used nationally in Europe to provide access to the new antibiotics are not sufficiently balanced by antibiotic stewardship efforts to calibrate the judicious use of the new antibiotics.

IMPLICATIONS: Antibiotic resistance is an immediate threat. The present review highlights areas where more systematic and uniform strategies across countries and geographical regions are warranted to improve evidence, availability, and use of new broad-spectrum antibiotics.

Для цитирования: Tängdén Thomas, Carrara Elena, Hellou Mona Mustafa, Yahav Dafna, Paul Mical. Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2024. DOI: 10.1016/j.cmi.2024.09.025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.